Nina Niu Sanford: Surprising Findings for Metastatic Pancreatic Cancer
Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post by Yakup Ergün, Medical Oncologist at Antalya City Hospital, adding:
“Surprising findings, especially b/c per forest plot, numerical improvement in OS for Gem/Abraxane v FFX actually appeared to be driven by ECOG 0 pts. Along with PASS-01 results & in absence of better biomarkers, I’m struggling to see in whom FFX is better (& if at all) for M1.”
Quoting Yakup Ergün‘s post:
“mFOLFIRINOX or S-IROX vs Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611)
mFOLFIRINOX or S-IROX was not found to be superior to gem+ nab-pac; in fact, gem+nab-paclitaxel showed numerically better outcomes.”
Title: Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial
Authors: Akihiro Ohba, Masato Ozaka, Junki Mizusawa, Takuji Okusaka, Satoshi Kobayashi, Taro Yamashita, Masafumi Ikeda, Ichiro Yasuda, Kazuya Sugimori, Naoki Sasahira, Kenji Ikezawa, Ikuya Miki, Naohiro Okano, Nobumasa Mizuno, Masayuki Furukawa, Hirofumi Shirakawa, Yusuke Sano, Hiroshi Katayama, Junji Furuse, Makoto Ueno
Read the Full Article.
More posts featuring Nina Niu Sanford.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023